Treating Hepatits C in HIV/HCV Coinfected Patients: A Global Challenge

Treating Hepatitis C in HIV/HCV
Coinfected Patients: A Global Challenge
Tuesday 9 July 2002, 20:00-22:00
Session Hall 1:3, in Palacio 1, Fira de Barcelona Conference Center

A(;1NI)A
20:0() \Why Treat Hepatitis C in
HIV/HCV-Coinfected Patients?
N ijehad S. Saab;, \ii)
20:20 Who Should Be Treated for Hepatitis C?
\"i lceSoi'an1o, Xii), i'l)
How Should Hepatitis C he Treated?
20:. 5 Setting Precedents: Lessons From Anti-HCV
Monoinfection Therapy
Rafill schan l11,vlu i
20:55 Treatment for Hepatitis C in HIV/HCVCoinfected Patients
Pat rice I'. (acoub, MIi)
21:15 Addressing the Challenges of Hepatitis C
Treatment in Coinfected Patients
I )oi.las TI I)ieterichl, Nii)
2/U:S" Q&A Session
All Iicultv
21:50 Concluding Remarks
Vicen te Sorian1o, Ii), 1hi1)
22:00 Adjourn
Light Tapas to Follow

IA A\RNIN(; ()i1j1:C I VIAs
Ih15sysm posium is designed for clinicians who see
patients with HIV/HC;V coinfeerion. At the end Of this
symposium1, participants will he able to:
" Recognize the magnitude and significance of the
problems of HCV infection and H IV/H-CV coinfection1
" Apply Current standards for identification and
management of HCV infection in HIV-Infected patients
" Consider the tise of emerging therapies that include
the use of pegylated interferon in combination with
ribavi ii n
" Manage adverse effects o)f interfero)n or pegintertcr)Ii
and ribavirin to achieve optimumll treatment outcomes
" IDevelop treatment strategies for H IV/H-( A',-coinfecied
patients, including those who are intravenotus drtuguss
and those with psychiatric disorders.

1 L1,:1A 'Il"B Ri1N ( (;O MiP 1

T iF 1) l' () R NI

l' () 1' R () (; KR i\ NI

Ni to

I *tk

Ad ( Ic"ss

Insttitu~tiont
(Iitv

Assistant'sN Noc
( 11th 'I cIrItoIt

('Mlt v,

I lot! intt Btcclottj

()iticc 1aX

c P a Ity
i'rictuc S c tt Itt'.J Int'tiiiotis casc
a A1~ctcoo

] (Ot hr (speritv).........................................J i~ (ilcbash{ -]J F 1i'ttl

O (taler (spediie)....................